Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform Presentation of additional analyses from FAP-Exd (AVA6103) study shows robust activity in PDX models with
Poolbeg Pharma CEO speaks on BioHub podcast in London
In this episode of The BioHub Podcast, Max sits down in person in London with Jeremy Skillington, CEO of Poolbeg Pharma.
Poolbeg Pharma receives UK clearance to begin cancer immunotherapy trial
Poolbeg Pharma plc (AIM: POLB) has received Clinical Trial Authorisation (CTA) from the Medicines and Healthcare products Regulatory Agency for its POLB 001 TOPICAL trial, marking a key regulatory milestone
Why 2026 could be a defining year for Poolbeg Pharma
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
ImmuPharma advances P140 partnering strategy following £6.5m raise
ImmuPharma PLC (AIM: IMM) said it is actively progressing partnering discussions for its lead autoimmune platform, P140, which remains its primary strategic focus for 2026.
Avacta Therapeutics (AIM: AVCT) Q1 2026 Business Update
LONDON and PHILADELPHIA – April 9, 2026 – Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today provides a business update through the first
Avacta Therapeutics (AIM: AVCT) Announces 2026 Science Day Event
LONDON and PHILADELPHIA – April 8, 2026 – Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to extend an open invitation for
How AI and Digital Databases are Revolutionizing Personal Healthcare
The Dawn of Data-Driven Wellness and Real-Time Surveillance
Avacta Therapeutics (AIM: AVCT) First patient treated in Phase 1 trial of AVA6103
Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) – a sustained-release pre|CISION® exatecan peptide drug conjugate
Poolbeg Pharma (AIM: POLB) Significant milestone for Poolbeg’s IP portfolio
Grant of first POLB 001 cancer immunotherapy-induced CRS patent Significant milestone for Poolbeg’s global intellectual property portfolio
Avacta raises £10m to fund next phase of cancer pipeline
Avacta Group has raised £10 million through an oversubscribed placing and subscription, issuing 15.87 million new shares at 63p, a discount of approximately 9.4% to the previous closing price.
Coiled Therapeutics plc (AIM: COIL) Admission to Trading and First Day of Dealings
Clinical stage oncology company joins AIM